Mark O'Neil-Johnson
Corporate Officer/Principal bei Sequoia Sciences, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Gary R. Eldridge | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | 25 Jahre |
William C. Rusnack | M | 79 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Joseph P. Conran | M | 78 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Stephen M. Notestine | M | 74 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | 25 Jahre |
Michael J. Mertz | M | 53 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
James P. Bick | M | 63 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Joel Schilling | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Michael Caparon | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 8 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Mark O'Neil-Johnson
- Persönliches Netzwerk